Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with NDMM received 4 cycles of KRd indu...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Jasielec, Jagoda K., Kubicki, Tadeusz, Raje, Noopur, Vij, Ravi, Reece, Donna, Berdeja, Jesus, Derman, Benjamin A., Rosenbaum, Cara A., Richardson, Paul, Gurbuxani, Sandeep, Major, Sarah, Wolfe, Brittany, Stefka, Andrew T., Stephens, Leonor, Tinari, Kathryn M., Hycner, Tyler, Rojek, Alexandra E., Dytfeld, Dominik, Griffith, Kent A., Zimmerman, Todd M., Jakubowiak, Andrzej J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2020
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7714092/
https://ncbi.nlm.nih.gov/pubmed/32735641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007522
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia